Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

65.38
-1.1000-1.65%
Volume:249.74K
Turnover:16.38M
Market Cap:5.46B
PE:-107.18
High:66.54
Open:66.51
Low:65.06
Close:66.48
52wk High:90.87
52wk Low:57.74
Shares:83.46M
Float Shares:73.65M
Volume Ratio:0.58
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6100
EPS(LYR):7.78
ROE:-7740.12%
ROA:2.46%
PB:-33.00
PE(LYR):8.40

Loading ...

PTC Therapeutics upgraded to Outperform from Market Perform at Leerink

TIPRANKS
·
Sep 14

PTC Therapeutics, Inc. : Leerink Partners Assumes Coverage with Outperform vs Market Perform Rating; Target Price $98 vs $70

THOMSON REUTERS
·
Sep 14

PTC Therapeutics Director Michael Schmertzler Disposes of USD 1.35 Million in Common Shares

Reuters
·
Sep 12

Wells Fargo Sticks to Its Buy Rating for PTC Therapeutics (PTCT)

TIPRANKS
·
Sep 02

PTC Therapeutics (PTCT) Stock May Trade Above Fair Value Despite An 81% Run

Simply Wall St.
·
Sep 02

PTC Therapeutics to Buy Drug Candidate from Sangamo for up to $211M

Dow Jones
·
Aug 29

PTC Therapeutics Director Michael Schmertzler Disposes of USD 1.82 Million in Common Shares

Reuters
·
Aug 29

PTC Therapeutics Acquires ST-920 Fabry Gene Therapy Rights

TIPRANKS
·
Aug 29

Broader Sephience PKU Data Could Be A Game Changer For PTC Therapeutics (PTCT)

Simply Wall St.
·
Aug 28

PTC Therapeutics Executives to Speak at Wells Fargo Healthcare Conference

Reuters
·
Aug 27

PTC Therapeutics Reports New Sephience PKU Trial and Real-World Data Showing Sustained Phe Control, Diet Liberalization

Reuters
·
Aug 24

PTC Therapeutics Director Michael Schmertzler Sells 24,000 Shares for $1.73 Million

Reuters
·
Aug 22

PTC Therapeutics Steps Into Rheumatoid Arthritis With New Phase 2 Study of PTC844

TIPRANKS
·
Aug 22

PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding Disposes of 2,813 Common Shares Worth $204,863.91

Reuters
·
Aug 20

The Bull Case For PTC Therapeutics (PTCT) Could Change Following Renal Data Progress For ST-920

Simply Wall St.
·
Aug 20

PTC Therapeutics Sets Up Long-Term FA Study, Adding a New Catalyst for PTCT Investors

TIPRANKS
·
Aug 15

PTC Therapeutics : Barclays Raises Target Price to $122 from $120

THOMSON REUTERS
·
Aug 14

Barclays Sticks to Their Buy Rating for PTC Therapeutics (PTCT)

TIPRANKS
·
Aug 14

Cantor Fitzgerald Sticks to Their Buy Rating for PTC Therapeutics (PTCT)

TIPRANKS
·
Aug 13

Bank of America Securities Reaffirms Their Buy Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
Aug 13